Vitamin D deficiency and insufficiency in HIV-infected children and young adults

Pediatric Infectious Disease Journal

Volumn 32, Issue 11, 2013, Pages 1240-1244

  Meyzer, Candice ^a,b   Frange, Pierre ^c,d   Chappuy, Hélène ^a,c   Desse, Blandine ^a,b   Veber, Florence ^d   Le Clésiau, Hervé ^e   Friedlander, Gérard ^a,b   Blanche, Stéphane ^c,d   Souberbielle, Jean Claude ^a,b   Tréluyer, Jean Marc ^a,b,c,f   Courbebaisse, Marie ^b,g  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Unité d'Immunologie et Hématologie Pédiatriques   (France)

^e Centre d'Examens de Santé de la Caisse Primaire d'Assurance Maladie de Seine Saint Denis   (France)

^f Pharmacologie   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

antiretroviral therapy; HIV infection; pediatrics; protease inhibitors; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; EFAVIRENZ;

ADOLESCENT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; RISK FACTOR; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ANALYSIS OF VARIANCE; ANTI-RETROVIRAL AGENTS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SKIN PIGMENTATION; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84886950842     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182a735ed     Document Type: Article

References (40)

1. Aldaz P, Moreno-Iribas C, Egüés N, et al. Mortality by causes in HIVinfected adults: comparison with the general population. BMC Public Health. 2011;11:300.
2. Kalayjian RC. Renal issues in HIV infection. Curr HIV/AIDS Rep. 2011;8:164-171.
3. Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS. 2011;6:266-271.
4. S tone B, Dockrell D, Bowman C, et al. HIV and bone disease. Arch Biochem Biophys. 2010;503:66-77.
5. Lake JE, Adams JS. Vitamin D in HIV-infected patients. Curr HIV/AIDS Rep. 2011;8:133-141.
6. Viard JP, Souberbielle JC, Kirk O, et al. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS. 2011;25:1305-1315.
7. Courbebaisse M, Souberbielle JC. Phosphocalcic metabolism: regulation and explorations. Nephrol Ther. 2011;7:118-138.
8. Courbebaisse M, Souberbielle JC, Prié D, et al. Non phosphocalcic actions of vitamin D. Med Sci (Paris). 2010;26:417-421.
9. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
10. Holick MF. Vitamin D: extraskeletal health. Endocrinol Metab Clin North Am. 2010;39:381-400, table of contents.
11. S ouberbielle JC, Body JJ, Lappe JM, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev. 2010;9:709-715.
12. Zhang R, Naughton DP. Vitamin D in health and disease: current perspectives. Nutr J. 2010;9:65.
13. Lips P. Worldwide status of vitamin D nutrition. J Steroid Biochem Mol Biol. 2010;121:297-300.
14. Rutstein R, Downes A, Zemel B, et al. Vitamin D status in children and young adults with perinatally acquired HIV infection. Clin Nutr. 2011;30:624-628.
15. S tephensen CB, Marquis GS, Kruzich LA, et al. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr. 2006;83:1135-1141.
16. Fitzpatrick T. Sun and skin. J Med Esthet. 1975;2:33-34.
17. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930.
18. S chwartz GJ, Haycock GB, Edelmann CM Jr, et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58:259-263.
19. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089-2100.
20. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53-58.
21. Garabédian M, Menn S, Walrant-Debray O, et al. Prevention of child and adolescent vitamin D deficiency. II. Validation of a decision-making abacus based on sun exposure and vitamin D intakes. Arch Pediatr. 2005;12:410-419.
22. Absoud M, Cummins C, Lim MJ, et al. Prevalence and predictors of vitamin D insufficiency in children: a Great Britain population based study. PLoS One. 2011;6:e22179.
23. Arpadi SHM, Horlick M, MacMahon DJ, et al. Vitamin D status and bone mineral density in perinatally HIV-infected children and adolescents living in New York City. In: XV International AIDS Conference. Bangkok, Thailand; 2004. Abstract TuPeB4467.
24. Gordon CM, Feldman HA, Sinclair L, et al. Prevalence of vitamin D deficiency among healthy infants and toddlers. Arch Pediatr Adolesc Med. 2008;162:505-512.
25. Kumar J, Muntner P, Kaskel FJ, et al. Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics. 2009;124:e362-370.
26. Institute of Medicine. Dietetary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2011.
27. P ekkinen M, Viljakainen H, Saarnio E, et al. Vitamin D is a major determinant of bone mineral density at school age. PLoS One. 2012;7:e40090.
28. Conesa-Botella A, Florence E, Lynen L, et al. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther. 2010;7:40.
29. Cozzolino M, Vidal M, Arcidiacono MV, et al. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17:513-520.
30. Yin M, Stein E. The effect of antiretrovirals on vitamin D. Clin Infect Dis. 2011;52:406-408.
31. Mueller NJ, Fux CA, Ledergerber B, et al.; Swiss HIV Cohort Study. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010;24:1127-1134.
32. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24:1923-1928.
33. P asquet A, Viget N, Ajana F, et al. Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use? AIDS. 2011;25:873-874.
34. Welz T, Childs K, Post FA. Do nevirapine and efavirenz affect vitamin D homeostasis similarly? AIDS. 2011;25:875-876.
35. Conrado T, Miranda-Filho Dde B, Bandeira F. Vitamin D deficiency in HIVinfected individuals: one more risk factor for bone loss and cardiovascular disease? Arq Bras Endocrinol Metabol. 2010;54:118-122.
36. Villamor E. A potential role for vitamin D on HIV infection? Nutr Rev. 2006;64(5 Pt 1):226-233.
37. Adeyemi OM, Agniel D, French AL, et al. Vitamin D deficiency in HIVinfected and un-infected women in the US. J Acquir Immune Defic Syndr. 2011;57:197-204.
38. O rmesher B, Dhaliwal S, Nylen E, et al. Vitamin D deficiency is less common among HIV-infected African-American men than in a matched cohort. AIDS. 2011;25:1237-1239.
39. Dao CN, Patel P, Overton ET, et al.; Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN) Investigators. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011;52:396-405.
40. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1375-1382.